Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $342.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price raised by Scotiabank from $338.00 to $342.00 in a report released on Monday morning,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday, March 21st. Finally, Bank of America boosted their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $316.25.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $270.02 on Monday. The company’s 50 day moving average is $260.34 and its two-hundred day moving average is $260.58. The firm has a market cap of $35.13 billion, a PE ratio of -124.43 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $28,000. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $35,000. Finally, True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.